Access to vaccine technologies in developing countries: Brazil and India

Julie B. Milstien, Patrick Gaulé, Miloud Kaddar

Research output: Contribution to journalArticlepeer-review

38 Citations (SciVal)


This study, conducted by visits, interviews, and literature search, analyzes how vaccine manufacturers in Brazil and India access technologies for innovative vaccines: through collaborations with academia and research institutions, technology transfer agreements with multinational corporations, public sector, or developing country organizations, or by importation and finishing of bulk products. Each has advantages and disadvantages in terms of speed, market, and ability to independently produce the product. Most manufacturers visited are very concerned about avoiding patent infringement, which might result in undeveloped or delayed products because of a lack of mastery of the patent landscape. Disregarding the patent picture could also threaten the market of a potential product. Although it is too soon to assess the effects of TRIPS on vaccine technology access in Brazil and India, a good understanding of intellectual property management will be useful. A case study on development of a new combination vaccine illustrates these findings.

Original languageEnglish
Pages (from-to)7610-7619
Number of pages10
Issue number44
Publication statusPublished - 1 Nov 2007


  • Intellectual property rights
  • Technology transfer
  • Vaccine innovation

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Access to vaccine technologies in developing countries: Brazil and India'. Together they form a unique fingerprint.

Cite this